Stay updated on Venetoclax and Lintuzumab-Ac225 in AML Patients Clinical Trial
Sign up to get notified when there's something new on the Venetoclax and Lintuzumab-Ac225 in AML Patients Clinical Trial page.

Latest updates to the Venetoclax and Lintuzumab-Ac225 in AML Patients Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedRevision: v3.3.3 was added to the record history and 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2' were removed from the footer. These updates affect metadata and footer content rather than study details or workflows.SummaryDifference0.2%

- Check22 days agoNo Change Detected
- Check44 days agoChange DetectedAdded Revision: v3.3.2 and removed Revision: v3.2.0 in the Record History section. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check51 days agoChange DetectedRemoved a general government funding/operating-status notice from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.7%

- Check65 days agoChange DetectedThe Record History page shows the same version list with dates; minor visual/layout changes are present. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check94 days agoChange DetectedMajor update: page now includes a government funding status notice and indicates version 3.2.0, replacing the previous 3.1.0.SummaryDifference13%

- Check101 days agoChange DetectedUpdated the page revision from v3.0.2 to v3.1.0, signaling a new release/version without altering core content or critical data.SummaryDifference0.3%

Stay in the know with updates to Venetoclax and Lintuzumab-Ac225 in AML Patients Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Venetoclax and Lintuzumab-Ac225 in AML Patients Clinical Trial page.